| Nov 1, 2025 | Artios Pharma | $120.0M Series D | Jake Simson, Nikola Trbovic | Andera Partners, EQT Life Sciences, Hakan Goker, M Ventures, Novartis Venture Fund, Pfizer Venture Investments, Invus, Janus Henderson Investors, LSP, Novartis, Omega Funds, Piper Heartland Healthcare Capital, Schroders Capital, Sofinnova Partners |
| Oct 1, 2025 | Affinia Therapeutics | $40.0M Series C | NEW Enterprise Associates | Atlas Venture, F Prime Capital, ED Mathers, Alexandria Venture Investments, ELI Lilly And Company, F Prime Capital, GV, Mass General Brigham Ventures, Perceptive Advisors |
| Sep 1, 2024 | Helaina | $45.0M Series B | Avidity Partners | Plum Alley Investments, Primary Venture Partners, Spark Capital, Hannah Bronfman, Scott Belsky, TOM Williams |
| Sep 1, 2024 | 858 Therapeutics | $50.0M Series B | Avidity Partners | ALI Behbahani, NEW Enterprise Associates, Versant Ventures |
| Apr 1, 2024 | Endeavor BioMedicines | $130.0M Series C | Ayurmaya, Karan Takhar | Atlas Venture, Hatteras Venture Partners, Omega Funds, RA Capital, Roche Venture Fund, Abrdn, Ally Bridge Group, Eckuity Capital, Fidelity Management & Research Company, Invus, Longitude Capital, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch BIO, SymBiosis, T. Rowe Price Associates, Velosity Capital, Woodline Partners |
| Aug 2, 2023 | CG Oncology | $105.0M Other Equity | Michael Rome, Giuliano Marostica | Acorn Bioventures, Ally Bridge Group, BVF Partners, Decheng Capital, Janus Henderson Investors, Longitude Capital, Malin Corporation, RA Capital Management |
| Dec 2, 2022 | Upstream | $140.0M Series B | Coatue, Dragoneer Investment Group | Define Ventures |
| Dec 1, 2022 | Upstream Health | $140.0M Series B | Aaron Weiner, Eric Jones | Define Ventures |
| Oct 6, 2022 | Nested Therapeutics | $90.0M Series A | Goldman Sachs | Cowen Healthcare Investments, Foresite Capital, Section 32 |
| Jan 7, 2022 | AN2 Therapeutics | $80.0M Series B | RA Capital Management | BVF Partners, Hatteras Venture Partners, Monashee Investment Management, Surveyor Capital |
| Oct 1, 2021 | Elemy | $220.0M Series B | Softbank | 9Yards Capital, Kevin Hartz, Accel, Acrew Capital, Adverb Ventures, Altair Capital Management, AME Cloud Ventures, Audrey Capital, Avalon Ventures, Benchstrength, Blitzscaling Ventures, Bond, Broadway Angels, C2 Investment, CapitalG, Coatue, Cota Capital, Craft Ventures, Daffy, Dragoneer Investment Group, Dream Machine, Flex Capital, Forerunner Ventures, FPV Fund, General Catalyst, Hardware Club, Helium 3 Ventures, Heretic Ventures, Incite Ventures, Liquid 2 Ventures, LOI Venture, Magnify Ventures, NFX, Pear VC, Polychain Capital, Quiet Capital, Redpoint Ventures, SciFi VC, Seven Seven SIX, Sherpalo Ventures, SNR, Sound Ventures, South Park Commons, SV Angel, Timespan Ventures, Tribe Capital, Y Combinator, Aaron Levie, Aaron Patzer, Aston Motes, Charlie Cheever, Clara Shih, Dharmesh Shah, Doug Sleeter, Drew Houston, Eduardo Haber, Eric Ries, Hiten Shah, Jared Leto, Jeff Seibert, Jeremy Stoppelman, Josh Silverman, Justin Rosenstein, Justin Timberlake, Kris Duggan, Larry Augustin, Louis Beryl, Marco Zappacosta, Mark Pincus, Matt Bellamy, Matt Mickiewicz, Phil Libin, SAM Altman, Seth Sternberg, Stacy Brown Philpot, Tien Tzuo, Tobias Lutke, Wayne Chang, Amity Ventures, Goodwater Capital, Metrodora Ventures, Premji Invest, Whale Rock Capital |
| Aug 3, 2021 | Zentera Therapeutics | $75.0M Series B | OrbiMed, Tybourne Capital Management | Casdin Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group, Surveyor Capital, Viking Global Investors |
| Aug 1, 2021 | GentiBio | $160.0M Series A | Andy Tran | Matrix Capital Management Company, JDRF T1D Fund, Novartis, OrbiMed, RA Capital Management, Seattle Children's Research Institute |
| Jul 27, 2021 | Artios | $152.0M Series C | Michelle Doig, Chen YU | Andera Partners, Mark Chin, DRX Capital, Invus, LSP, M Ventures, Piper Heartland Healthcare Capital, RTW Investments, Schroders Capital, Sofinnova Partners, Soleus Capital, SV Health Investors, Tetragon Financial Group |
| Jul 1, 2021 | Artios Pharma | $150.0M Series C | Michelle Doig, Chen YU | Andera Partners, EQT Life Sciences, Hakan Goker, M Ventures, Novartis Venture Fund, Pfizer Venture Investments, Arix Bioscience, Caas Capital Management, Deep Track Capital, Invus, LSP, Novartis, Piper Heartland Healthcare Capital, RTW Investments, Schroders Capital, Sofinnova Partners, Soleus Capital, SV Health Investors, Tetragon Financial Group |
| Jul 1, 2021 | Exo | $220.0M Series C | Zach Scheiner | BlackRock, Pura Vida Investments, Sands Capital |
| May 20, 2021 | Biotheryx | $92.0M Series E | Farallon Capital Management | Alexandria Venture Investments, Deep Track Capital, Irving Investors, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Tekla Capital Management, Wedbush Healthcare Partners |
| May 1, 2021 | Affinia Therapeutics | $110.0M Series B | Caroline Stout, Farallon Capital Management | Atlas Venture, F Prime Capital, ED Mathers, NEW Enterprise Associates, Casdin Capital, F Prime Capital, GV, Lonza, Mass General Brigham Ventures, Octagon Capital, Perceptive Advisors, RA Capital Management, TCGX, Woodline Partners |
| Mar 1, 2021 | Century Therapeutics | $160.0M Series C | Casdin Capital | Versant Ventures, Qatar Investment Authority, Marshall Wace, Octagon Capital, OrbiMed, RA Capital Management, Federated Kaufmann Fund, Fidelity Management & Research Company, Leaps BY Bayer, Logos Capital |
| Mar 1, 2021 | Amunix | $120.0M Series B | Viking Global Investors | Frazier Healthcare Partners, ArrowMark Partners, Bain Capital Life Sciences, BlackRock, Caas Capital Management, Casdin Capital, Franklin Templeton, Janus Henderson Investors, Longitude Capital, Omega Funds, Polaris Partners, Redmile Group, Venrock |
| Mar 1, 2021 | Crossover Health | $170.0M Series D | Deerfield Management | Norwest Venture Partners, Foresite Capital, Irving Investors, OrbiMed, Perceptive Advisors, PFM Health Sciences, The Private Shares Fund |
| Mar 1, 2021 | Caribou Biosciences | $120.0M Series C | Farallon Capital Management, Santhosh Palani, Phd, CFA, Jeffrey Long Mcgie | 1435 Capital Management, 6TH MAN Ventures, Afore Capital, DFJ, E1 Ventures, Flucas Ventures, Founders Co OP, Heavybit, Invariantes Fund, Kleiner Perkins, KRM Interests LLC, LombardStreet Ventures, Maverick Capital, Menlo Ventures, Mouro Capital, Necessary Ventures, QED Investors, Robert Bosch Venture Capital, Starbridge Venture Capital, Sterling Equity, William GUO, Xstarpartners, Adam Marchick, Andy Rubin, Dylan Taylor, Hugo Angelmar, Ravi Grover, Richard Cooperstein, ROB Meyerson, SRI Batchu, Sung HO Choi, AbbVie Ventures, Adage Capital Management, Avego Bioscience Capital, Heritage Medical Systems, Invus, Janus Henderson Investors, Lifesci Venture Partners, Monashee Investment Management, Point72, Pontifax, Tekla Capital Management, The Leukemia & Lymphoma Society |
| Feb 1, 2021 | Cyteir Therapeutics | $80.0M Series C | Derek Dirocco | Advanced Technology Ventures, Aisling Capital, Dolby Family Ventures, Novo Ventures, Venrock, Acuta Capital Partners, Ally Bridge Group, Ample Plus Fund, Caas Capital Management, Droia Ventures, Janus Henderson Investors, Lightstone Ventures, Osage University Partners |
| Dec 16, 2020 | Neurogene | $115.0M Series B | Oleg Nodelman | Alexandria Venture Investments, ArrowMark Partners, Ascendant BioCapital, BlackRock, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Redmile Group, Samsara BioCapital |
| Aug 18, 2020 | Chinook Therapeutics | $106.0M Other Equity | — | Ally Bridge Group, Apple Tree Partners, EcoR1 Capital, Janus Henderson Investors, Monashee Investment Management, Northleaf Capital Partners, OrbiMed, Rock Springs Capital, Samsara BioCapital, Sphera Biotech Master Fund, Surveyor Capital, Versant Ventures |
